Summary & Overview
HCPCS Level II J0744: Ciprofloxacin Injection for Intravenous Infusion, 200 mg
HCPCS Level II code J0744 represents a 200 mg intravenous infusion of ciprofloxacin, an antibiotic used for serious bacterial infections requiring IV therapy. This code matters nationally as it standardizes billing and clinical documentation for IV ciprofloxacin administration across acute and outpatient infusion settings, supporting consistent reimbursement and utilization tracking for an important antimicrobial agent.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for IV ciprofloxacin, typical sites of service where J0744 is used, and the payer landscape relevant to reimbursement and claims processing. The analysis covers benchmark practices for coding and billing, common modifiers and billing considerations (listed separately), and the implications for facility and professional service lines.
This publication provides clinicians, coders, and billing professionals with the essential facts needed to identify when J0744 applies, understand payer coverage relevance, and locate further operational details. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0744 describes an injection of ciprofloxacin for intravenous infusion, 200 mg. This code denotes the administration of the antibiotic ciprofloxacin intravenously in a 200 mg dose.
-
Service type: Intravenous antimicrobial infusion
-
Typical site of service: Hospital inpatient, hospital outpatient, emergency department, infusion center, or other facility capable of IV medication administration
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with a serious Gram-negative bacterial infection requiring intravenous antimicrobial therapy receives J0744 (injection, ciprofloxacin for intravenous infusion, 200 mg). Typical scenarios include complex urinary tract infections, pyelonephritis, intra-abdominal infections, or hospital-acquired/ventilator-associated pneumonia where ciprofloxacin susceptibility is documented and IV administration is indicated for severity or gastrointestinal intolerance. The clinical workflow: admission or ED evaluation → diagnostic testing (blood/urine cultures, imaging as indicated) → infectious diseases or hospitalist consult for antimicrobial selection → order for J0744 placed in the electronic health record with indication, dose, frequency, and duration → pharmacy verifies dose, prepares IV infusion per hospital infusion protocols → nurse administers infusion with monitoring for infusion reactions and adverse effects (e.g., QT prolongation, tendonopathy) → documentation of dose, lot/batch if required, and administration site; ongoing clinical reassessment guides conversion to oral therapy when appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | Use when part of a single-use vial dose is discarded and payor requires reporting of discarded biologic/drug. |